Research Feeds

View All
Characterizing the gut microbiota in females with infertility and preliminary results of a water-soluble dietary fiber intervention study A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson’s Disease Diagnosis of the menopause: NICE guidance and quality standards Causes of Death in End-Stage Kidney Disease: Comparison Between the United States Renal Data System and a Large Integrated Health Care System Factors affecting the absorption and excretion of lead in the rat Factors associated with age at menarche, menstrual knowledge, and hygiene practices among schoolgirls in Sharjah, UAE Cadmium transport in blood serum The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic Structured Exercise Benefits in Euthyroid Graves’ Disease: Improved Capacity, Fatigue, and Relapse Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease A Pilot Microbiota Study in Parkinson’s Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome Integrated Microbiome and Host Transcriptome Profiles Link Parkinson’s Disease to Blautia Genus: Evidence From Feces, Blood, and Brain Gut microbiota modulation: a narrative review on a novel strategy for prevention and alleviation of ovarian aging Long-term postmenopausal hormone therapy and endometrial cancer

What is the best strategy for moving microbiome-based therapies for functional gastrointestinal disorders into the clinic? Original paper

Researched by:

  • Divine Aleru ID
    Divine Aleru

    User avatarI am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.

    Read More

September 28, 2025

  • Metals
    Metals

    Heavy metals play a significant and multifaceted role in the pathogenicity of microbial species.

  • Microbes
    Microbes

    Microbes, short for microorganisms, are tiny living organisms that are ubiquitous in the environment, including on and inside the human body. They play a crucial role in human health and disease, functioning within complex ecosystems in various parts of the body, such as the skin, mouth, gut, and respiratory tract. The human microbiome, which is […]

Researched by:

  • Divine Aleru ID
    Divine Aleru

    User avatarI am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.

    Read More

Last Updated: 2025-09-28

Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.

Divine Aleru

I am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.

What was studied?

The study focuses on strategies to integrate microbiome-based therapies for functional gastrointestinal disorders (FGIDs), such as irritable bowel syndrome (IBS), into clinical practice. It examines the role of the gut microbiome in FGID pathogenesis, explores various therapeutic approaches such as fecal microbiota transplantation (FMT) and probiotics, and highlights the need for more precise microbiome-targeted treatments.

Who was studied?

The review primarily considers the clinical and experimental studies related to FGIDs, specifically IBS. It integrates findings from human clinical trials and animal models that investigate the association between the microbiome and gastrointestinal function. The review also discusses challenges in translating these findings to therapeutic strategies.

Most important findings

The study reveals that microbiome alterations, particularly in individuals with IBS, are associated with gastrointestinal dysfunction, including changes in gut motility, visceral hypersensitivity, and intestinal permeability. Despite significant advances in understanding the microbiome’s role, studies often show inconsistent results, with microbiome-based therapies failing to consistently address specific disease mechanisms. The review calls for a systems-based approach, integrating multi-omics data and patient-specific characteristics to improve therapeutic outcomes. The study emphasizes the importance of patient stratification based on microbial alterations and pathophysiological measurements.

Key implications

This review outlines the gap between microbiome research and clinical application. It suggests that to move microbiome-based therapies into the clinic effectively, future studies should combine multiple layers of data, including microbial composition, metabolomics, and clinical measurements. Personalized treatment strategies should be developed based on these integrated data, which can help target the underlying causes of FGIDs. Moreover, employing longitudinal studies will be crucial in understanding the dynamic nature of these disorders and identifying responders to specific therapies.

Microbiome-Targeted Interventions (MBTIs)

Microbiome Targeted Interventions (MBTIs) are cutting-edge treatments that utilize information from Microbiome Signatures to modulate the microbiome, revolutionizing medicine with unparalleled precision and impact.

Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. Recent research has focused on the gut microbiota's role in IBS, aiming to identify specific microbial signatures associated with the condition.

Fecal Microbiota Transplantation (FMT)

Fecal Microbiota Transplantation (FMT) involves transferring fecal bacteria from a healthy donor to a patient to restore microbiome balance.

Probiotics

Probiotics are live microorganisms that offer significant health benefits when administered in adequate amounts. They primarily work by modulating the gut microbiome, supporting a balanced microbial ecosystem. Probiotics have been shown to improve gut health, modulate immune responses, and even influence metabolic and mental health disorders. With growing evidence supporting their therapeutic potential, probiotics are increasingly recognized for their role in treating conditions like irritable bowel syndrome (IBS), antibiotic-associated diarrhea (AAD), and even mental health conditions like depression and anxiety through their impact on the gut-brain axis.

Join the Roundtable

Contribute to published consensus reports, connect with top clinicians and researchers, and receive exclusive invitations to roundtable conferences.